Conditioning regimens for allogeneic stem cell transplants

Current Opinion in Hematology

Volumn 7, Issue 6, 2000, Pages 339-342

  Barrett, A John ^a  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; CYTARABINE; FLUDARABINE; IDARUBICIN; MELPHALAN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;

ACUTE GRANULOCYTIC LEUKEMIA; CHRONIC LYMPHATIC LEUKEMIA; DRUG POTENCY; DRUG SAFETY; GRAFT REJECTION; GRAFT SURVIVAL; GRAFT VERSUS LEUKEMIA EFFECT; HLA MATCHING; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY CARCINOMA; LYMPHATIC LEUKEMIA; METASTASIS; MORTALITY; MYELODYSPLASTIC SYNDROME; MYELOID LEUKEMIA; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; REVIEW; STEM CELL TRANSPLANTATION; WHOLE BODY RADIATION;

GRAFT VS HOST DISEASE; GRAFT VS TUMOR EFFECT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOCOMPATIBILITY TESTING; HUMANS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS;

EID: 0033784505     PISSN: 10656251     EISSN: None     Source Type: Journal    
DOI: 10.1097/00062752-200011000-00003     Document Type: Review

References (27)

1. Reinventing bone marrow transplantation: Reducing toxicity using nonmyeloablative preparative regimens and induction of graft-versus-malignancy
2. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases
3. Full donor chimerism predicts for graft-versus-host disease, graft-versus-marrow and graft-versus-malignancy effects following a non-myeloablative preparative regimen
4. Stem cell escalation enables HLA-disparate haematopoietic transplants in leukaemia patients
5. CD34 cell dose predicts relapse and survival following T cell depleted HLA-identical hematopoietic stem cell transplantation for hematological malignancies
6. Stable mixed chimerism and tolerance using a nonmyeloablative preparative regimen in a large animal model
7. Mixed lymphohaemopoietic chimerism and graft-versus-lymphoma effects after non-myeloablative therapy and HLA-mismatched bone-marrow transplantation
8. Stable mixed hematopoietic chimerism in dog leucocyte antigen-identical littermate dogs given lymph node irradiation before and pharmacologic immunosuppression after marrow transplantation
9. Synergism between mycophenolate mofetil and cyclosporine in preventing graft-versus-host disease among lethally-irradiated dogs given DLA-nonidentical unrelated marrow grafts
10. Stable mixed hematopoietic chimerism in dogs given donor antigen, CTLA-4 Ig and 100cGy total body irradiation before and pharmacologic immunosuppression after marrow transplant
11. Mini-allografts: Ongoing trials in humans
12. Transplant-lite: Induction of graft-versus-malignancy using a fludarabine-based nonablative chemotherapy and allogeneic blood progenitor transplantation as treatment for lymphoid malignancy
13. Transplant lite using fludarabine-cyclophosphamide (FC) for low grade lymphoma (LGL)
14. Reduction in the frequency of transplant-related complications in patients with chronic myeloid leukemia undergoing BMT preconditioned with a new non-myeloablative drug combination
15. Molecular remission of chronic myelogenous leukaemia following a non-myeloablative allogeneic peripheral blood stem cell transplant: In vivo and in vitro evidence for a graft-versus-leukaemia (GVL) effect
16. Evidence of cytogenetic and molecular remission by allogeneic cells after immunosuppressive therapy alone
17. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: Harnessing graft-versus-leukemia without myeloablative therapy
18. Successful treatment of metastatic renal cell carcinoma with a non-myeloablative allogeneic peripheral blood progenitor cell transplant: Evidence for a graft-versus-tumor effect
19. Regression of metastic renal cell carcinoma following nonmyeloablative allogenic peripheral blood stem cell transplantation
20. Transplantation of anergic histoincompatible bone marrow allografts
21. Comparison of preparative regimens in transplants for children with acute lymphoblastic leukemia
22. Aspects concerning busulfan pharmacokinetics and bioavailability
23. Idarubicin to intensify the conditioning regimens of autologous bone marrow transplantation for patients with acute myeloid leukemia in first complete remission
24. A dose escalation study of total body irradiation followed by high-dose etoposide and allogeneic blood stem cell transplantation for the treatment of advanced hematologic malignancies
25. Radioimmunotherapy for the intensification of conditioning before stem cell transplantation: Differences in dosimetry and biokinetics of 188Re- and 99m Tc-labeled anti NCA-95 Mabs
26. Phase I study of (131)I-anti-CD45 antibody plus cyclophosphamide and total body irradiation for advanced acute leukemia and myelodysplastic syndrome
27. Therapy of B-cell lymphomas with monoclonal antibodies and radioimmunoconjugates: The Seattle experience